Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-742X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants ; day:2 ; month:11 ; year:2020 ; pages:1-9
Journal of thrombosis and thrombolysis ; (2.11.2020), 1-9
- Urheber
-
Wallvik, Niklas
Renlund, Henrik
Själander, Anders
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11239-020-02319-w
- URN
-
urn:nbn:de:101:1-2020121520381554572732
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wallvik, Niklas
- Renlund, Henrik
- Själander, Anders
- SpringerLink (Online service)
Ähnliche Objekte (12)
Increased Platelet Adhesiveness in Patients with Venous Thromboembolic Disease
Screening for Cancer in Patients with Acute Venous Thromboembolic Disease
Factors associated with venous thromboembolic disease due to failed thromboprophylaxis
Management of bleeding in patients treated with direct oral anticoagulants
Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review
Observed risk of recurrent bleeding and thromboembolic disease in COVID-19 patients with gastrointestinal bleeding
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants
The Association between Factor XI Deficiency and the Risk of Bleeding, Cardiovascular, and Venous Thromboembolic Events
Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
Increased Platelet Adhesiveness in Patients with Venous Thromboembolic Disease
Screening for Cancer in Patients with Acute Venous Thromboembolic Disease
Factors associated with venous thromboembolic disease due to failed thromboprophylaxis
Management of bleeding in patients treated with direct oral anticoagulants
Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review
Observed risk of recurrent bleeding and thromboembolic disease in COVID-19 patients with gastrointestinal bleeding
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants
The Association between Factor XI Deficiency and the Risk of Bleeding, Cardiovascular, and Venous Thromboembolic Events
Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
Increased Platelet Adhesiveness in Patients with Venous Thromboembolic Disease
Screening for Cancer in Patients with Acute Venous Thromboembolic Disease
Factors associated with venous thromboembolic disease due to failed thromboprophylaxis
Management of bleeding in patients treated with direct oral anticoagulants
Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review
Observed risk of recurrent bleeding and thromboembolic disease in COVID-19 patients with gastrointestinal bleeding
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants
The Association between Factor XI Deficiency and the Risk of Bleeding, Cardiovascular, and Venous Thromboembolic Events